Key result
Elevated CRP velocity is linked to ~30% higher risk of severe systolic dysfunction after STEMI.
Why the study?
Data regarding the association of C-reactive protein velocity with echocardiographic parameters assessing left ventricular systolic and diastolic function in STEMI patients treated with primary PCI is lacking.
Does elevated C-reactive protein velocity predict severe left ventricular systolic and diastolic dysfunction in patients with STEMI treated with primary PCI?
Cohort (n=1,059)
No
Does elevated C-reactive protein velocity predict severe left ventricular systolic and diastolic dysfunction in patients with STEMI treated with primary PCI?
Answers are grounded in this paper and cite their sources.
C-reactive protein velocity (CRPv) serves as a sensitive and readily available early biomarker for predicting severe systolic and diastolic left ventricular dysfunction in patients with STEMI.
C-reactive protein velocity (CRPv), defined as the change in wide-range CRP concentration divided by time, is an inflammatory biomarker associated with increased morbidity and mortality in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous intervention (PCI). However, data regarding CRPv association with echocardiographic parameters assessing left ventricular systolic and diastolic function is lacking. Echocardiographic parameters and CRPv values were analyzed using a cohort of 1059 patients admitted with STEMI and treated with primary PCI. Patients were stratified into tertiles according to their CRPv. A receiver operating characteristic (ROC) curve was used to evaluate CRPv optimal cut-off values for the prediction of severe systolic and diastolic dysfunction. Patients with high CRPv tertiles had lower left ventricular ejection fraction (LVEF) (49% vs. 46% vs. 41%, respectively; p < 0.001). CRPv was found to independently predict LVEF ≤ 35% (HR 1.3 CI 95% 1.21–1.4; p < 0.001) and grade III diastolic dysfunction (HR 1.16 CI 95% 11.02–1.31; p = 0.02). CRPv exhibited a better diagnostic profile for severe systolic dysfunction as compared to CRP (area under the curve 0.734 ± 0.02 vs. 0.608 ± 0.02). In conclusion, For STEMI patients treated with primary PCI, CRPv is a marker of both systolic and diastolic dysfunction. Further larger studies are needed to support this finding.
No takes yet. Share an insight, caveat, or question.
Banai et al. (2022) conducted a cohort in STEMI treated with primary PCI (n=1,059). C-reactive protein velocity (CRPv) vs. Lower CRPv was evaluated on Severe systolic dysfunction (LVEF ≤ 35%) (HR 1.3, 95% CI 1.21-1.41, p=< 0.001). Elevated C-reactive protein velocity (CRPv) was independently associated with severe systolic dysfunction in STEMI patients treated with primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: